Short answer
Intellia Therapeutics, Inc. (NTLA) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 results and business updates announced for quarter ended June 30, 2026.
Intellia Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 results and business updates announced for quarter ended June 30, 2026
- Full financial and operating details contained in furnished Exhibit 99.1
- Investor focus: clinical pipeline developments and cash outlook in the accompanying release
Item EX-99.1 · Exhibit EX-99.1
- Positive Phase 3 HAELO data: lonvo-z reduced attacks 87% versus placebo, with 62% attack-free and therapy-free versus 11%
- FDA BLA acceptance anticipated in second half of 2026, with potential U.S. launch in first half of 2027
- Nex-z Phase 3 enrollment resumed; MAGNITUDE-2 ATTRv-PN enrollment targeted for completion in second half of 2026
- Genomic analysis identified an HLA allele associated with highest liver transaminase elevations, creating a safety-monitoring and regulatory focus
- Cash $628.4M after $195M net offering proceeds, expected to fund operations at least into 2028; Q2 net loss $106.6M
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Intellia Therapeutics, Inc. 8-K filings
Get the next NTLA 8-K as it lands
Follow NTLA for push alerts, or ask the research agent what this filing means.